Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Eli Lilly and Company (NYSE: LLY ), the Pharma whose valuation has more than quadrupled on a five-year basis, almost exclusively down to its "miracle" weightThe group is for both novice and experienced biotech inve ...